Homepage > Company > Media > Pharma News > 2020 > Moderna to file for FDA emergency use authorization for COVID-19 vaccine

Moderna to file for FDA emergency use authorization for COVID-19 vaccine

Moderna announced that it plans to file with the FDA Monday for an emergency use authorization for its coronavirus vaccine, which the company said has an efficacy rate of 94.1%.

Why it matters: Moderna will become the second company to file for a vaccine EUA after Pfizer did the same earlier this month, potentially paving the way for the U.S. to have two COVID-19 vaccines in distribution by the end of the year. The company said its vaccine has a 100% efficacy rate against severe COVID cases.

What to watch: By the end of 2020, Moderna expects to have approximately 20 million vaccine doses available in the U.S, and plans to manufacture 500 million to 1 billion doses globally in 2021, according to a press release.

What they're saying: “This positive primary analysis confirms the ability of our vaccine to prevent COVID-19 disease with 94.1% efficacy and importantly, the ability to prevent severe COVID-19 disease. We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic and help prevent severe disease, hospitalizations and death,” said Moderna CEO Stéphane Bancel.

October 30, 2020

https://www.axios.com/

Read also

Merck gains rights to LaNova’s PD-1/VEGF bispecific antibody in deal worth over $3.2bn

Merck & Co – known as MSD outside the US and Canada – has entered into an exclusive global licensing agreement worth over $3.2bn to advance LaNova Medicines’ investigational PD-1/VEGF bispecific...

Rectify Pharma Presents Preclinical Data Supporting Development of Lead Candidate RTY-694 at The Liver Meeting® 2024

Rectify Pharmaceuticals, Inc., a biotechnology company developing positive functional modulators (PFMs), small molecule therapeutics that restore and enhance membrane protein function, today ...

Ideaya hires Gilead leader to head up commercialization push

Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive who played a role in the commercialization of Trodelvy and Opdivo.

Silo Pharma discloses ‘promising results’ from preclinical study on SPC-15

Silo Pharma announced promising results from a preclinical study on SPC-15. This new formulation, which targets both the serotonin 5-HT4 receptor, 5-HT4R, and the NMDA receptor, NMDAR, has shown poten...